دورية أكاديمية
أعرض في EDS

2-(3-Bromophenyl)-8-fluoroquinazoline-4-carboxylic Acid as a Novel and Selective Aurora A Kinase Inhibitory Lead with Apoptosis Properties: Design, Synthesis, In Vitro and In Silico Biological Evaluation.

التفاصيل البيبلوغرافية
العنوان: 2-(3-Bromophenyl)-8-fluoroquinazoline-4-carboxylic Acid as a Novel and Selective Aurora A Kinase Inhibitory Lead with Apoptosis Properties: Design, Synthesis, In Vitro and In Silico Biological Evaluation.
المؤلفون: Elsherbeny MH; Chemical and Biological Integrative Research Center, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea.; Division of Bio-Medical Science & Technology, KIST School, University of Science and Technology, Seoul 02792, Korea.; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, Giza 12566, Egypt., Ammar UM; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0NR, UK., Abdellattif MH; Department of Chemistry, College of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia., Abourehab MAS; Department of Pharmaceutics, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.; Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Minia University, Minia 61519, Egypt., Abdeen A; Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, Benha University, Toukh 13736, Egypt., Ibrahim SF; Department of Clinical Sciences, College of Medicine, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia., Abdelrahaman D; Department of Clinical Sciences, College of Medicine, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia., Mady W; Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Roh EJ; Chemical and Biological Integrative Research Center, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea.; Division of Bio-Medical Science & Technology, KIST School, University of Science and Technology, Seoul 02792, Korea., Elkamhawy A; BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University-Seoul, Goyang 10326, Korea.; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
المصدر: Life (Basel, Switzerland) [Life (Basel)] 2022 Jun 10; Vol. 12 (6). Date of Electronic Publication: 2022 Jun 10.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101580444 Publication Model: Electronic Cited Medium: Print ISSN: 2075-1729 (Print) Linking ISSN: 20751729 NLM ISO Abbreviation: Life (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, 2011-
مستخلص: New quinazoline derivatives were designed based on the structural modification of the reported inhibitors to enhance their selectivity toward Aurora A. The synthesized compounds were tested over Aurora A, and a cytotoxicity assay was performed over NCI cell lines to select the best candidate for further evaluation. Compound 6e (2-(3-bromophenyl)-8-fluoroquinazoline-4-carboxylic acid) was the most potent compound among the tested derivatives. A Kinase panel assay was conducted for compound 6e over 14 kinases to evaluate its selectivity profile. Further cell cycle and apoptosis analysis were evaluated for compound 6e over the MCF-7 cell line at its IC 50 of 168.78 µM. It arrested the cell cycle at the G1 phase and induced apoptosis. Molecular docking was performed to explore the possible binding mode of compound 6e into the active site. It showed significant binding into the main pocket in addition to potential binding interactions with the key amino acid residues. Accordingly, compound 6e can be considered a potential lead for further structural and molecular optimization of the quinazoline-based carboxylic acid scaffold for Aurora A kinase selective inhibition with apoptosis properties.
التعليقات: Erratum in: Life (Basel). 2024 Mar 22;14(4):. (PMID: 38672808)
References: J Med Chem. 2011 Jan 13;54(1):312-9. (PMID: 21128645)
Expert Opin Ther Pat. 2011 Jun;21(6):857-84. (PMID: 21591849)
Sci Rep. 2017 Oct 13;7(1):13131. (PMID: 29030590)
Front Oncol. 2016 Jan 18;5:307. (PMID: 26835416)
J Ethnopharmacol. 2017 Feb 23;198:302-312. (PMID: 28108382)
Cancer Biol Ther. 2012 Sep;13(11):1034-41. (PMID: 22895067)
J Med Chem. 2007 May 3;50(9):2213-24. (PMID: 17373783)
Molecules. 2018 Apr 26;23(5):. (PMID: 29701706)
Eur J Med Chem. 2021 Oct 5;221:113495. (PMID: 34020340)
J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12. (PMID: 2359136)
Molecules. 2015 Jan 09;20(1):1031-45. (PMID: 25584833)
Pharmaceuticals (Basel). 2021 Nov 30;14(12):. (PMID: 34959648)
J Med Chem. 1997 Jun 6;40(12):1794-807. (PMID: 9191956)
Oncogene. 2005 Jul 28;24(32):5005-15. (PMID: 16049526)
Eur J Med Chem. 2018 Sep 5;157:1361-1375. (PMID: 30196060)
Eur J Med Chem. 2020 Mar 15;190:112108. (PMID: 32058239)
Expert Opin Drug Discov. 2011 Mar;6(3):291-307. (PMID: 21556291)
J Comput Chem. 2003 Oct;24(13):1549-62. (PMID: 12925999)
J Med Chem. 2009 May 28;52(10):3300-7. (PMID: 19402633)
Eur J Med Chem. 2017 Nov 10;140:1-19. (PMID: 28918096)
Molecules. 2021 Sep 01;26(17):. (PMID: 34500757)
Angew Chem Int Ed Engl. 2017 Jan 9;56(2):587-590. (PMID: 27936308)
J Med Chem. 2009 May 14;52(9):2629-51. (PMID: 19320489)
Eur J Med Chem. 2017 Dec 1;141:322-334. (PMID: 29031076)
Toxicol Lett. 2018 Jul;291:77-85. (PMID: 29654831)
J Med Chem. 2013 Nov 27;56(22):9122-35. (PMID: 24195668)
Sci Rep. 2019 Feb 11;9(1):1746. (PMID: 30741973)
معلومات مُعتمدة: 2E31140 Korea Institute of Science and Technology
فهرسة مساهمة: Keywords: Aurora A; anticancer; apoptosis; cell cycle; kinases; molecular docking; quinazoline
تواريخ الأحداث: Date Created: 20220624 Latest Revision: 20240427
رمز التحديث: 20240427
مُعرف محوري في PubMed: PMC9225547
DOI: 10.3390/life12060876
PMID: 35743907
قاعدة البيانات: MEDLINE
الوصف
تدمد:2075-1729
DOI:10.3390/life12060876